Investing.com - Regeneron Pharma (NASDAQ:REGN) reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $25.8 on revenue of $5.14B. Analysts polled by Investing.com anticipated EPS of $17.91 on revenue of $3.97B.
Regeneron Pharma shares are up 20.25% from the beginning of the year and are trading at $580.95 , down-from-52-week-high.They are outperforming the S&P 500 which is up 17.22% from the start of the year.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma's report follows an earnings beat by J&J on Wednesday, July 21, 2021, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on Thursday, July 15, 2021 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar